MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
MiRXES secures two trophies at the SBR Management Excellence Awards 2021
The company was awarded the Team of the Year and Executive of the Year awards for Biotechnology.
Read Here
Advertise
Sign Up
Commentary
Contract 'of' or 'for' Service? Or a New Legal Creature? The Singapore Platform Worker’s Bill